key: cord-0271595-z5ydfdyn authors: Ains, A.; Heneghan, C.; Aronson, J. K.; DeVito, N. J.; Richards, G. C. title: Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports to prevent future deaths date: 2021-04-30 journal: nan DOI: 10.1101/2021.04.28.21256272 sha: c54b24e31126bc88009e501afbb386fbe8188417 doc_id: 271595 cord_uid: z5ydfdyn Background: The global burden of cardiovascular disease (CVD) is forecast to increase, and anticoagulants will remain important medicines for its management. Coroners' Prevention of Future Death reports (PFDs) provide valuable insights that may enable safer and more effective use of these agents. Objective: To identify CVD-related PFD reports highlighting the use or lack of anticoagulants as having caused or contributed to deaths. Methods: We conducted a retrospective observational study of coronial case reports in England and Wales between 2013 and 2019. We screened 3037 PFDs for inclusion and used content analysis to assess concerns raised by coroners and who responded to them. Results: We identified 113 CVD-related PFDs (113 deaths) involving anticoagulants. Warfarin (36%), enoxaparin (11%), and rivaroxaban (11%) were the most common anticoagulants reported. In 14 cases, the coroner mentioned that the administration of an anticoagulant may have prevented the death. Concerns most frequently raised by coroners included poor systems (31%), poor communication (25%), and failures to keep accurate medical records (25%). These concerns were most often directed to NHS trusts (29%), hospitals (10%), and general practices (8%), but had national importance. Nearly two-thirds (60%) of PFDs had not received responses from such organisations, which are mandatory under regulation 28 of the Coroners' (Investigations) Regulations 2013. Conclusions: We created a tool (https://preventabledeathstracker.net/) that bring together coroner reports to identify important lessons related to preventable deaths. Here we examined instances of premature deaths from CVD involving anticoagulants. National organisations, healthcare professionals, and prescribers should take actions to address these concerns, to improve the use of anticoagulants in patients with CVD. Cardiovascular disease (CVD) is the leading cause of mortality worldwide [1, 2] . In 2019, 18 .6 million deaths (33% of all deaths) were due to CVD [3] , with a projection of 24 million annual deaths by 2030 [4] . In England and Wales, CVD was responsible for almost a quarter of all deaths in 2019 [5, 6] . Premature mortality from CVD in England has also been attributed to greater socioeconomic inequalities in people under 75 years of age [7] . In patients at high risk of strokes, heart attacks, deep vein thrombosis, or pulmonary embolism, anticoagulation is one possible prophylactic intervention [8] . Anticoagulants target different points of the coagulation cascade, helping to prevent blood clot formation and the adverse effects of excessive clotting. Three main types of anticoagulants are outlined in NICE guidelines: low molecular weight heparin (e.g. enoxaparin), vitamin K antagonists (e.g. warfarin), and direct-acting oral anticoagulants (DOACs; e.g. rivaroxaban). The effectiveness of anticoagulants for cardiovascular disease is well established. For example, adjusted-dose warfarin reduced stroke by 62% (95% CI: 48% to 72%) in patients with atrial fibrillation [9] . However, the narrow therapeutic index and frequent laboratory monitoring needed with warfarin administration have led to the development of DOACs [10] . Bleeding associated with warfarin therapy is among the top three adverse drug reactions that cause hospital admissions in England [11] . In English primary care, prescribing of anticoagulants increased from 15 million doses to 33 million between January 2014 and August 2019 [12] . Coroners' reports, previously named Rule 43 reports and now called Prevention of Future Death reports (PFDs), are mandated under paragraph 7 of Schedule 5 of the Coroners and Justice Act 2009, when the coroner believes that action is necessary to prevent a death [13] . PFDs are sent to specific individuals or organisations, who, under regulation 28 and 29 of the Coroners (Investigations) Regulations 2013, have a duty to respond within 56 days of the date of report [14] . Previous analysis of coroners' reports has shown that anticoagulants were the drugs most commonly reported to have been involved in fatal medication errors in England and Wales [15] . But that research examined only a proportion (n=500) of all published coroners' reports. Building on previous research, we aimed to assess all available PFDs on deaths in individuals with CVD, in whom the use or lack of use of anticoagulants caused or contributed to the death. We sought to discover: 1) what concerns were highlighted by coroners; 2) to which individuals or organizations PFDs were addressed; 3) whether responses were made by the individuals or organizations to whom the PFDs were sent. We designed a retrospective observational study and preregistered our study protocol on an open repository [16] . We used the STROBE reporting guideline to write our manuscript. PFDs are openly available on the Courts and Tribunals Judiciary website [17] . We used web scraping to automatically collect PFDs, and from the output created the Preventable Deaths Database and the Preventable Deaths Tracker: https://preventabledeathstracker.net/ [18] . The code to create the scraper is openly available on GitHub [19] and has been previously described [20] . The Preventable Deaths Database contains: the case reference number; the date of the report; the name of the deceased; the coroner's name; the coroner's jurisdiction; the category of death (defined by the Chief Coroners' office); to whom the report was sent; and the URL to the Judiciary website. For population data on deaths from CVD, we used the most recent (2001-2019) dataset of deaths registered in England and Wales, released by the Office for National Statistics in 2020 (ONS) [5] . We examined all cases (n=3037) in the Preventable Deaths Database from July 2013 (the first date on which they were uploaded to the Judiciary website) to December 2019. We screened the cases independently in duplicate (AA & GCR) to determine whether CVD caused or contributed to the death using a pre-defined algorithm (Supplementary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.28.21256272 doi: medRxiv preprint For included cases, one study author (AA) manually extracted the following variables into a predesigned Google Sheet: the individuals or organizations to whom reports were sent, who responded, the due date of response and the date received; date of death; the dates on which the inquest started and ended; age; sex; setting or location of death; medical cause(s) of death; the coroner's conclusion(s) of the inquest; relevant medical, mental health, and social history; whether any substance(s) were implicated in the death and the type of substance(s); coroner's concern(s) and actions proposed by the coroner. To determine the annual deaths from CVD in England and Wales, we filtered the ONS data [5] for deaths caused by conditions listed under chapter IX of ICD-10 (ICD-10 codes: I00-I99). We summed the number of reports written each year and compared the totals with ONS mortality data for CVD. We used descriptive statistics to report the quantitative findings and performed content analysis [21] to classify the concerns and actions raised by coroners with categories derived inductively. We calculated a response rate for each organisation as the proportion of reports to which a response was submitted over the total number received. Responses were further classified as either on-time (delivered within 56 days), late (submitted after 56 days), or overdue (when no response was found on the Judiciary website). A response rate of 100% means that individual or organisation adhered to regulation 28 of the Coroners' (Investigations) Regulations 2013 and responded to all PFDs issued by coroners. We used Python v3.7 in Jupyter Notebooks with pandas, seaborn, and matplotlib libraries to analyse the data and create figures. The data, statistical code, and study materials are openly available via the Open Science Frame [22] and GitHub [23] . In 659 cases (22% of all PFDs) CVD caused or contributed to the death ( Figure 1 ). Of the CVD-related PFDs, 17% (n=113) involved or mentioned the use or lack of an anticoagulant. Over the seven-year study period, there was a median of 16 (IQR: 15-17) CVD-related anticoagulant PFDs each year (Supplementary Table 1 ). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 30, 2021. ; North East (3%) of England wrote very few (Table 1) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We identified 335 individual concerns raised by coroners in the 113 cases. Using content analysis, we categorised these concerns into 51 groups and five higher-order themes, including communication, failure to follow protocols, education and training, resources, and safety ( Table 2 ). The most common concerns were poor systems (31%), poor communication (25%), failure to keep accurate medical records (25%), and failures or delays in having appropriate assessments done (17%). Concerns most frequently belonged to the theme of following protocols (36%), followed by communication (22%), and safety issues (21%). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 30, 2021. In 82% of CVD-related PFDs involving anticoagulants, coroners stated that "action should be taken" (Supplementary Table 2 Table 2 ). For the 113 CVD-related PFDs involving anticoagulants, coroners sent 181 reports to individuals or organisations, collated into 37 groups (Table 3) . NHS Trusts (29%), hospitals (10%), and general practices (8%) were addressed most frequently. By statute addressees must respond to the coroner within 56-days, but only 29% responded on time; 11% . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.28.21256272 doi: medRxiv preprint responded late and 60% were overdue. Medical societies (0%) and royal colleges (0%) had the lowest response rates, while NHS entities had the highest, albeit with a collective response rate of 51%. Ranking recipients by response rate and response time, NHS 111, NHS Wales, and CCGs performed best (Supplement Table 3 ). Government 17 5 29 18 12 71 DHSC 7 3 43 14 29 57 Local authorities 3 1 33 33 0 67 Welsh Government 7 1 14 14 0 86 Professional bodies 21 4 19 10 10 81 CQC 6 2 33 17 17 67 NICE 8 2 25 13 13 75 GMC 2 0 0 0 0 100 BMA 1 0 0 0 0 100 GDC 1 0 0 0 0 100 MHRA 1 0 0 0 0 100 AACE 1 0 0 0 0 100 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 30, 2021. Association 1 0 0 0 0 100 Others 18 3 17 11 6 83 Police 1 1 100 0 100 0 Private companies 4 1 25 25 0 75 Care homes 9 1 11 11 0 89 Carewatch 1 0 0 0 0 100 Highway maintenance 1 We identified 113 premature deaths from cardiovascular disease involving anticoagulants. In 88% of cases, the use of one anticoagulant or more resulted in death. In 12% of cases, death was attributed to the absence of anticoagulation. We found wide geographical variation in the issuing of PFDs and the type of information reported, with coroners in Greater Manchester writing the most. Coroners raised many concerns, which we categorised into five themes: failure to follow protocols, communication, safety issues, education and training, and the lack of adequate resources. Most of these concerns were addressed locally and under regulation 28, 109 individuals or organisations were overdue in their response to such concerns. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.28.21256272 doi: medRxiv preprint We used a reproducible data-collection method to examine all available PFDs from inception to 2019, which provided an estimated 40-fold time saving [20] , and reduced the potential for selection bias. However, the PFDs included in our study depend on the working practices of coroners and the Chief Coroner's Office in uploading PFDs and their responses to the website. The 113 PFDs cannot therefore represent all preventable deaths from CVD involving anticoagulants in England and Wales. There were also missing data; for example, 32% of PFDs did not report age and 16% did not specify the type of anticoagulant; this may be attributed to lack of PFD training provided to coroners. Our study builds on prior research that evaluated smaller samples of coroners' reports [15, [24] [25] [26] [27] . Compared with previous studies [26, 28] , we did not identify a sex imbalance. However, we found that most PFDs were addressed locally, as shown by Ferner et al. [15] , which means that valuable lessons were not widely disseminated and may be why we found that coroners repeatedly expressed similar concerns, in line with former research [25] . This questions whether PFDs are fulfilling their purpose. Similar to Fox and Jacobson [26] , we found pronounced geographical variation in the issuing of PFDs and poor response rates. A review of the coronial system in England and Wales highlighted lack of accountability, leadership, and quality assurance [29] . Since there is no system in place for enforcing or auditing compliance with regulation 28 or assessing the quality of PFDs and the adequacy of responses and actions taken to prevent deaths, our findings show that the system has scope for improvement. Fortunately, the value of PFDs as a tool for improving clinical practice is being recognised, and efforts are underway to widely disseminate these lessons to healthcare professionals, policymakers, and the public [30] [31] [32] [33] [34] . Concerns raised by coroners provide lessons for prescribers and policymakers on the safety and proper use of therapies. During the COVID-19 pandemic, patients were switched from warfarin to other oral anticoagulants, given the need for less frequent blood testing [35] . Drugs such as andexanet alfa could prove critical in the outcome of patients with severe bleeding during treatment with apixaban or rivaroxaban. Since the coroner expressed concerns (Case: 2018-0032), NICE has drafted an appraisal for andexanet alfa [36] , and its publication is expected on 12 May 2021 [37] . There has also been a phased launch of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.28.21256272 doi: medRxiv preprint andexanet alfa in UK hospitals [38] . However, it is unclear whether this was a direct result of the PFD, since no response from the MHRA was published on the Judiciary website. When PFDs are addressed to the appropriate recipients at the national level, their actions can help prevent deaths. For example, a PFD was sent to NICE when the deceased suffered a fall while taking an anticoagulant without having the appropriate neuroimaging performed (Case: 2019-0106). The coroner's concerns were acknowledged in a NICE surveillance report [39] and resulted in updating of the NICE guideline on head injury, to emphasise that people taking DOACs should be investigated with the same care as those taking warfarin [40] . However, we also identified unaddressed concerns about national guideline; three-quarters of PFDs sent to NICE have no responses listed on the Judiciary website. Restarting warfarin after a head injury is particularly important, as delays could leave the patient at risk of a stroke, but resuming too soon may lead to haemorrhage. A retrospective review of the medical charts of 256 patients admitted to a trauma centre in West Texas between 2009 and 2012 showed that patients who resumed anticoagulant therapy at 7-10 days after the injury had the best prognosis [41] . PFDs can therefore be used to update guidance and inform future prospective cohort studies. Our study provides a database and resource (https://preventabledeathstracker.net/) for future evaluations of PFDs. Further content analysis should be used to assess the 181 responses to the 113 PFDs, to assess the adequacy of actions taken or proposed to prevent deaths. Future research could use our open data to examine coroners' concerns in the 546 CVD-related PFDs not involving anticoagulants and their responses. In building the web scraper to collect PFDs, we found various inconsistencies and omissions on the Judiciary website, which should be addressed to improve the quality of the data. The missing data from PFDs we have highlighted reveal target areas for coronial training in the writing of PFDs. PFDs provide valuable lessons when prescribing anticoagulants and managing patients with CVD. However, it is unclear whether actions are being taken to incorporate such lessons. To improve patient safety, PFDs should be widely disseminated. Cardiovascular diseases (CVDs) CVD risk assessment and management Global Health Data Exchange The Future of CVD [Internet]. who.int Deaths registered in England and Wales -21st century mortality [Internet]. Office for National Statistics Articles Premature mortality attributable to socioeconomic inequality in England between Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis Anticoagulation drug therapy: A review Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients Trends in anticoagulant prescribing: A review of local policies in English primary care The Coroners (Investigations) Regulations Deaths from Medicines: A Systematic Analysis of Coroners' Reports to Prevent Future Deaths Deaths from cardiovascular disease: A systematic analysis of coroners' reports to prevent future deaths in England and Wales Courts and Tribunals Judiciary Preventable Deaths Tracker GitHub -georgiarichards/georgiarichards.github.io [Internet How we learnt to stop worrying and love web scraping Demystifying content analysis Deaths from cardiovascular disease: A systematic analysis of coroners' reports to prevent future deaths in England and Wales Preventing Future Deaths from Medicines: Responses to Coroners' Concerns in England and Wales A thematic analysis of the prevention of future deaths reports in healthcare from HM coroners in England and Wales 2016-2019. J Patient Saf Risk Manag How well do Regulation 28 reports serve future public health and safety? Analysis of 1263 deaths in four general practices Local variations in reporting deaths to the coroner in England and Wales: A postcode lottery? A review of the coroner system in England and Wales: A commentary Coroners' concerns to prevent harms: A series of coroners' case reports to serve patient safety and educate the public, clinicians and policy-makers Alcohol-based hand sanitisers: A warning to mitigate future poisonings and deaths Emollients and smoking: a fire hazard that could be prevented to reduce future deaths Diclofenac in adolescents: Diagnosing and treating gastrointestinal adverse drug reactions can prevent future deaths Tramadol: Repeated prescriptions and repeated warnings OpenSAFELY: impact of national guidance on switching from warfarin to direct oral anticoagulants (DOACs) in early phase of COVID-19 pandemic in England Andexanet alfa for reversing anticoagulation CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Andexanet alfa surveillance of head injury: assessment and early management (NICE guideline CG176) [Internet]. NICE CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity